

Active Ingredient: Aprepitant 



Dosage Form; Route: For suspension; oral 



Recommended Studies: Two studies 





1.Type of study: Fasting


Design: Single-dose, two-way crossover in-vivo

Strength: 125 mg

Subjects: Healthy males and non-pregnant, non-lactating females, general population.

Additional Comments: Follow the preparation and administration instructions as described inthe approved drug label.





2.Type of study: Fed


Design: Single-dose, two-way crossover in-vivo

Strength: 125 mg

Subjects: Healthy males and non-pregnant, non-lactating females, general population.

Additional Comments: Follow the preparation and administration instructions as described inthe approved drug label.



Analytes to measure (in appropriate biological fluid): aprepitant in plasma 

Bioequivalence based on (90% CI): aprepitant 

Waiver request of in-vivo testing: Not applicable 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 




